CCRN
Cross Country Healthcare Inc
13.30$
+0.0%
vs. previous close
Closing price · As of: Jul 28, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.6% | 62.9% | 61.1% | 59.7% | 56.0% | 56.3% | 56.9% | 56.4% | 55.8% | 54.8% | 65.4% | 66.1% | |
| 0.1% | 2.0% | 2.5% | 0.8% | 11.5% | 10.7% | 13.9% | 14.0% | 14.7% | 18.4% | 24.2% | 23.4% | |
| 0.1% | 2.0% | 2.5% | 0.8% | 11.5% | 10.7% | 13.9% | 14.0% | 14.7% | 18.4% | 24.2% | 23.4% | |
| 64.4% | 59.8% | 57.2% | 57.5% | 43.1% | 44.7% | 41.2% | 40.8% | 39.4% | 35.2% | 39.2% | 40.8% | |
| 0.9% | 0.7% | – | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 3.2% | – | – | – | – | – | – | – | – | – | – | – | |
| 17.8% | 19.1% | 19.9% | 20.9% | 22.5% | 22.7% | 22.9% | 23.4% | 24.4% | 25.1% | 14.2% | 14.1% | |
| 7.8% | 8.9% | 8.0% | 9.1% | 9.6% | 9.4% | 7.2% | 6.9% | 9.0% | 9.0% | 6.2% | 9.1% | |
| 39.0% | 33.6% | 30.3% | 27.8% | 27.2% | 28.9% | 28.9% | 27.4% | 25.6% | 24.2% | 28.1% | 30.7% | |
| 28.0% | 25.9% | 21.9% | 19.8% | 18.3% | 20.2% | 20.4% | 18.9% | 17.4% | 15.9% | 17.3% | 20.1% | |
| 0.4% | 0.4% | 0.4% | 0.4% | 0.3% | 0.3% | 0.4% | 0.3% | 0.2% | 0.2% | 0.3% | 0.2% | |
| 18.1% | 16.2% | 0.4% | 10.6% | 9.2% | 9.8% | 1.0% | 9.8% | 8.8% | 7.9% | 0.5% | 10.6% | |
| 4.0% | – | – | – | – | – | – | – | – | – | – | – | |
| 61.0% | 66.4% | 69.7% | 72.2% | 72.8% | 71.1% | 71.1% | 72.6% | 74.4% | 75.8% | 71.9% | 69.3% | |
| 28.1% | 32.4% | 35.1% | 37.2% | 37.3% | 37.1% | 37.0% | 37.8% | 38.1% | 38.3% | 27.4% | 26.4% | |
| 4.6% | 5.0% | 5.1% | 5.3% | 5.6% | 5.5% | 5.5% | 5.6% | 5.9% | 6.0% | 7.2% | 7.0% |
Data as of: July 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.